Citi analyst Mohit Bansal lowered his price target for Coherus Biosciences shares to $23 from $33 after removing Humira and Enbrel from his model. Investors will unlikely assign value to Humira and Enbrel biosimilars "anytime soon" given the lack of intellectual property clarity and competition, Bansal tells investors in a research note. The analyst, however, still sees value in Coherus even without Humira. The company's meeting with the FDA is key and a subsequent resubmission will likely make investors more confident in Neulasta biosimilar approval, Bansal contends. He keeps a Buy rating on Coherus Biosciences.